估值26.4亿元！冲刺港股IPO！

Core Viewpoint - Hunan Maijizhi Biotechnology Co., Ltd. (referred to as "Maijizhi") has officially submitted its IPO application to the Hong Kong Stock Exchange, marking a significant step in its growth as a biopharmaceutical company focused on innovative biologics for inflammatory and immune diseases [3][9]. Company Overview - Established in 2016, Maijizhi has developed a pipeline of eight innovative candidate products, including core product MG-K10 and key products MG-014 and MG-013, with three candidates already in clinical stages [5][7]. - MG-K10 is a long-acting anti-IL-4Rα antibody designed for the precise treatment of moderate to severe atopic dermatitis and asthma, with a half-life 2 to 3.5 times longer than similar antibodies on the market [5][7]. Clinical Development - MG-K10 has made significant progress in clinical research, having completed Phase II trials for atopic dermatitis and currently undergoing Phase III trials for atopic dermatitis, asthma, nodular prurigo, and Phase II/III trials for seasonal allergic rhinitis in China [7][8]. - The company has established a comprehensive clinical development plan, with key milestones including the submission of a Biologics License Application (BLA) expected in the second half of 2025 [8]. Financial and Investment Highlights - Maijizhi has secured a total investment of 1.5 billion yuan from Xiangjiang Guotou, holding a 6.59% stake in the company, which has facilitated its clinical research progress [9]. - The company completed a Pre-IPO financing round in July, raising 260 million yuan, resulting in a post-investment valuation of 2.64 billion yuan [8].